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CURTIS B. WILSON
Department of immunology, Research institute of Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, California, USA
Tubulointerstitial nephritis (TIN), as studied experimentally,
can be induced by many of the same humoral immune mecha-
nisms now recognized to cause immune forms of glomerular
injury [reviewed in 1—5] (Table 1). In addition, there is compel-
ling evidence of direct cellular immune involvement in some
forms of TIN. In general, however, less is known about the
immunopathogenesis of human TIN than its glomerular coun-
terpart. For example, the specific mechanisms responsible for
many of the instances of TIN associated with drug hypersensi-
tivity remain unclear. Much of what is known comes from the
study of experimental models of TIN. In addition, these model
systems are being used to forward the understanding of control
of nephritogenic immune reactions [6—101. This paper will focus
on a discussion of the different immune mechanisms that have
been shown to contribute to TIN in experimental models and
their extension to human TIN as appropriate.
Anti-TBM antibody-associated models of TIN
A number of models of TIN produced by immunization (with
adjuvants) using homologous or heterologous tubular basement
membranes (TBM) or less purified fractions of kidney homoge-
nate have been described. These models are characterized by
the production and tubular fixation of anti-TBM antibodies and
have been extensively studied in guinea pigs, rats, and mice.
The models in different species have both common and unique
features and form the basis for much of what is known regarding
the immunopathogenesis of TIN, including the varying contri-
butions of humoral (antibody) and cellular (effector T cell)
immune mechanisms.
At least two different types of anti-TBM antibody reactivity
can develop. In the first type, the reactive antigens are confined
to segments of the TBM and their expression is controlled
genetically, at least in rats and humans. In the other type, the
reactive antigens are found in GBM and other basement mem-
branes, as well as in the TBM. Access of circulating antibody to
basement membrane antigens also varies. For example, heter-
ologous anti-GBM antibody preparations frequently contain
antibodies that react in vitro with TBM and other epithelial
basement membranes, whereas in vivo they do not fix well to
TBM. Heterologous or monoclonal anti-TBM antibodies have
shown little or no ability to cause interstitial nephritis [11, 12].
In vivo binding of anti-basement membrane antibodies, such as
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those reactive with alveolar basement membrane, has been
shown to be favored by local events which can alter normal
anatomical barriers, as can be induced by oxygen or hydrocar-
bon toxicity in the lung [13—15].
The spontaneous appearance of anti-TBM antibodies has
been noted in the lupus prone New Zealand black/white hybrid
mice and in a Samoyed dog with TIN [16, 171. The latter
observation may be of interest because the Samoyed has
recently been noted to suffer from a hereditary nephritis not
unlike Alport's syndrome in humans, a condition associated
with alterations in glomerular basement membrane (GBM)
antigen content [18, 191.
Guinea pig models
Experimentally, the first models of anti-TBM antibody-asso-
ciated TIN were induced in the guinea pig in 1971 by immuni-
zation with rabbit cortical basement membrane in adjuvants
[20]. Anti-GBM and anti-alveolar basement membrane antibod-
ies [20—221 were also present, but glomerulonephritis or lung
lesions were not a prominent feature of the experimental lesion
characterized by a striking mononuclear interstitial infiltrate,
giant cell formation and tubular dysfunction (glycosuria). The
giant cells were demonstrated to be in contact with the TBM;
such contact was followed by perforation and phagocytosis of
TBM fragments [231. When a bovine (Boy) TBM immunogen
was used to immunize the guinea pigs, the anti-TBM antibodies
were found to react with the noncollagenous portion of the
TBM, whereas the minimally nephritogenic anti-GBM antibod-
ies reacted with collagenous determinants as demonstrated by
collagenase solubilization (CS) of basement membrane frac-
tions [22]. Strain differences in susceptibility were demon-
strated and shown to segregate with the major histocompatibil-
ity complex [241. Guinea pig TIN was easily transferred with
antibody, but not immune cells [25, 26], suggesting a prominent
role for anti-TBM antibody in its immunopathogenesis. Both
IgG1 and IgG2 transferred the disease and generated further
production of anti-TBM antibody by the recipient [271. Trans-
placental transfer of these autoantibodies has been detected,
but the quantities bound were apparently insufficient to induce
disease [28]. Anti-TBM antibody production and disease devel-
opment has been decreased by injection of heterologous anti-
idiotypic antibodies [29].
The guinea pig TIN can be induced in C4-deficient guinea
pigs, but not in the recipients of nephritogenic amounts of
antibody who were depleted of C3 with cobra venom factor
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Table 1. Immune mechanisms in the pathogenesis of
tubulointerstitial nephritis
Humoral mechanisms
Antibodies reactive with structural antigens:
Basement membrane antigens—TBM, GBM/TBM, ?TBM-drug
conjugates, etc.
Antibodies producing immune deposit formation and/or cellular
cytotoxicity:
Immune complex disease—Circulating or trapped soluble
exogenous or endogenous antigens (Serum proteins, drugs,
DNA, idiotypic antigens, etc.)
Renal cell products or surface antigens—Heymann's nephritis
brush border antigens, Tamm-Horsfall protein, ?planted
antigens (drugs, antibiotics, etc.), ?microbial antigens
Cellular mechanisms
Delayed type hypersensitivity:
Aggregated proteins, cell surface antigens, TBM antigens, ?drugs
Immunization with renal antigens:
Isologous kidney homogenate, homologous renal basement
membrane preparations
Spontaneous TIN of kdkd mice:




(CVF); complement factor B, but not C4, has been found along
the TBM [30—32]. Transfer of the disease can also be blocked by
irradiation (640 rads) induced leukopenia, and could be recon-
stituted with bone marrow but not lymphoid cells [33, 341.
A role for cellular immunity in the guinea pig model was
suggested by the demonstration of cellular sensitivity to the
immunizing antigen present in lymphoid cells; such cells mi-
grated to the kidney and were cytotoxic to fetal kidney mono-
layers [35, 36]. Lymphocyte supernatants stimulated fibroblast
proliferation and collagen synthesis [37]. Guinea pig anti-TBM
antibodies enhanced in vitro antibody-dependent cellular cyto-
toxicity [38]. A chemo-attractant for macrophages (but not
polymorphonuclear leukocytes) was found to be enriched in
renal venous blood of guinea pigs with TIN and its appearance
was reported to appear coincident with the macrophage influx
[39]. An attempt to enhance the disease by abrogation of
supressor T cells with high-dose cyclophosphamide was unsuc-
cessful; on the contrary this treatment inhibited antibody dep-
osition and largely prevented the lesion [40].
The induction of anti-TBM antibody in the guinea pig follow-
ing sodium aurothiomalate (gold)-induced tubular injury has
been reported recently [41]. The antibody was noted 20 weeks
after the first administration of gold salt. The kidney lesion was
complicated in some animals by glomerular mesangial deposits
and antibody reactive with renal tubular antigens (prepared like
the Heymann nephritis antigen, Fx1A) was present. These
antibodies to renal tubular antigens also reacted with the
glomerular deposits. Anti-basement membrane antibody pro-
duction has also been found in other forms of nephrotoxicity
induced by heavy metals, for example, the anti-GBM antibody
formation provoked by mercuric chloride in rats [42].
Rat models
In rats, anti-TBM antibody-associated TIN, followed by a
form of Heymann's nephritis, has been induced in Brown
Norway (BN) rats by immunization with Sprague-Dawley rat
kidney homogenate in adjuvants [43]. Circulating and elutable
anti-TBM antibodies were found in this model, and transfer of
immune serum was reported to produce a mild TIN. A Hey-
mann's nephritis-like lesion and anti-TBM antibodies have also
been induced by immunization with the mouse Engelbreth-
Holm-Swarm tumor used to obtain purified basement mem-
brane components [44]. The compounding problem of Hey-
mann's nephritis can be avoided by using heterologous antigen,
such as bovine (Boy) TBM [45]. Subcapsular placement of
immune cells from rats immunized with Boy TBM resulted in
the transfer of a mild TIN [46].
Lewis (LEW) rats lack an accessible form of the BN TBM
antigen responsible for TIN [43, 45]. They can produce anti-
TBM antibodies but they do not bind in vivo. In contrast, they
do possess the antigen, found in GBM as well as TBM, that can
bind human anti-GBM antibodies. The allotypic difference in
TBM antigens has been used to induce anti-TBM antibodies by
transplanting TBM antigen-positive (TBM Ag) LEW XBN F1
kidneys into TBM Ag LEW recipients [47]. The presence of
an analogous allotypic difference in a TBM was subsequently
found in a patient who developed anti-TBM antibodies after
receiving a TBM Ag transplant [48]. The TBM Ag differences
in various rat strains have been explored in other studies [1, 49],
including one in which anti-TBM antibodies were induced by
transfer of parenteral TBM Ag lymphocytes into a TBM Ag
F1 hybrid [50]. Female Lew rats induced to develop anti-TBM
antibodies transferred these transplacentally to F1 TBM Ag
hybrids, with some offspring showing tubular atrophy and mild
inflammatory reactions [51]. Genetically, the TBM alloanti-
gen(s) appear to be inherited as a dominant gene that does not
segregate with the MHC (RT1) genes [52—54] but which is linked
to the genes for pinkeye dilution and albinism on the first
linkage group [55, 56].
Polymorphonuclear leukocytes (PMN) dominate the initial
inflammatory cell infiltrate in the Boy TBM-induced BN TIN
and is co-incident with anti-TBM antibody and complement
deposition 8 to 10 days after immunization [57]. The PMNs are
rapidly replaced by a mononuclear infiltrate, so that by day 13
cells recovered from the infiltrate by teasing and purification on
Ficoll Hypaque gradients are 10% Ig (B cells), 60% W3/25
(includes T helper cells), 9% OX8 (includes T suppressor
cells), and 9% esterase (monocytes). The ratio of W3I25 to
OX8 cells are higher in the kidney than in the spleen or
peripheral blood. Monocyte infiltration, detected as esterase
cells in the tissue sections, increases after 2 weeks and is even
more obvious in the infiltrate cell suspensions; it approaches
40% of the total cells recovered from such infiltrates by day 28
when fibrosis and other histologic evidence of chronicity of the
lesion are apparent. Giant cell formation is a feature of the
lesion and these cells are believed to derive from monocytes
that evolve into epithelioid cells which fuse and have increased
metabolic activity [58—61]. The infiltrating T cells are sensitized
to the immunogen as well as to purified protein derivative (PPD)
present in the adjuvant, but not to a variety of autologous BN
renal antigens [62]. The apparent lack of reactivity of autolo-
gous renal antigens may be due to technical problems, including
inadequate renal tubular antigen preparations or to the presence
of suppressor T cell populations in the test mixture. As will be
described in the next section, the contribution of Ia and other
cell surface antigens on the renal tubular cell may also be a
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factor in the autologous reactivity. Systemic administration of
the sensitized BN lymph node cells, after propagation in vitro
with Boy TBM, transfers TIN to normal BN recipients and is
accompanied by the production and tubular fixation of anti-
TBM antibodies.
As with anti-GBM antibody disease and other forms of
immune renal injury, the induction of disease in the Boy TBM
to BN rat model can be related quantitatively (elution study
[45]) and temporally to antibody binding. Detailed study of the
circulating antibodies in this model shows that they reacted to
both Boy and BN TBM antigens, whereas antibodies recovered
from the affected kidneys by elution were concentrated for
reactivity against particulate BN and collagenase solubilized
BN TBM antigens [63]. Heterologous anti-idiotypic antibody-
induced suppression of disease correlated with a decrease in the
anti-BN CS TBM antibody without affecting reactivity to Boy
particulate or CS TBM, and only lowering anti-BN particulate
antibody activity insignificantly [64]. Anti-idiotypic antibodies
induced by cell administration also inhibited disease develop-
ment [65]. Recently, an anti-idiotypic antibody capable of
binding to a cross-reactive epitope shared by several monoclo-
nal anti-TBM antibodies was noted to be protective, and to
depress delayed type hypersensitivity to TBM antigen when
given at time of immunization [66]. Of therapeutic interest was
the observation that it also diminished progression when given
to rats with established disease 2 weeks after immunization.
Rats immunized to produce disease do not develop a detect-
able autologous anti-idiotypic antibody response, It has been
shown that this response is suppressed by a cyclophosphamide
sensitive RT7.l, 0X8 suppressor cell, suggesting that such
cells, appearing shortly after immunization, may limit the host's
specific ability to regulate the self-destructive anti-TBM anti-
body response [67].
In contrast to the guinea pig, serum transfer of anti-TBM
antibody-associated TIN was difficult in the rat models [43, 50,
62]. Recently, however, small amounts (3 to 5 ml) of LEW
anti-BN renal basement membrane (RBM) antibody were found
to induce lesions similar to those found in the actively immu-
nized BN TIN model, allowing the first quantitative assessment
of the antibody fixation in TIN [68]. Utilizing paired label
isotopic techniques, the antibody was shown to fix to the TBM
gradually, peaking 5 to 6 days after administration, and then
slowly disappearing. The earliest induction of disease in the
transfer model occurred at approximately 24 hours, when about
170 g of antibody per gram of kidney had bound. This
compared to about 75 tgIg of anti-GBM antibody for induction
of glomerular injury in the rat [69]. The initial focal lesions
contained predominately mononuclear cells, with up to 20%
PMN in areas of damaged tubules. By 6 days, the lesions of TIN
were fully developed with tubular destruction, giant cells, and
focally-severe mononuclear cell infiltration. By immunofluores-
cence, the transferred IgG fixed in a linear pattern in focal areas
of TBM initially. With time or increased dose a diffuse, linear,
cortical TBM fixation of IgG with focally brighter areas was
found. Elution of IgG from kidneys of rats injected with
anti-TBM antibodies confirmed the increasing IgG fixation over
6 days, and showed that on day 6 anti-CS BN RBM antibody
was selectively concentrated in the eluate compared to serum.
The transfer lesions contained C3 deposits in areas of cellular
infiltration. Complement depletion by administration of CVF
prior to antibody administration greatly diminished the number
of destructive lesions accompanied by giant cells without af-
fecting antibody fixation [68]. When CVF was used to decom-
plement BN rats with active Boy TBM immunization, the initial
8 to 10 day PMN phase was markedly diminished, again without
affecting the quantity of antibody bound [70]. Some mononu-
clear cell infiltration was observed, but this was less than in the
unmodified model, suggesting that a portion of the mononuclear
component of the lesion was independent of the initi'al comple-
ment-dependent PMN infiltration and was either a complement-
independent humoral event or related to underlying cellular
immune events.
The BN TIN was modulated by preimmunization using
antigen with incomplete Freund's adjuvant, a treatment that
favors induction of suppressor cells [71]. The suppression was
MHC-restricted and mediated by OX8 T cells (suppressor
phenotype), which bound antigen and shared idiotypes cross-
reactive with the anti-TBM antibodies. Anti-TBM antibody
production was also somewhat less, and since this is critical for
the initial phase of this model, the study does not exclude the
importance of humoral immunity in the model. In contrast to
heterologous TBM antigen immunization, BN rats do not
develop TIN after being given autologous TBM. This has been
shown to be due to a suppressor cell mechanism which could be
blocked by pretreatment with cyclophosphamide [721.
In the BN model, dietary protein restriction inhibited delayed
type hypersensitivity to TBM antigen and diminished disease in
BN TIN without affecting antibody titers [73]. Active suppres-
sion was not demonstrated by admixture cotransfer of cells.
Daily cyclophosphamide impaired immune response and pre-
vented the BN TIN lesion if given early and in large amounts
[74]. Low doses enhanced disease presumably by altering
suppressor cell mechanisms. When given in high doses to rats
with anti-TBM antibody fixation and established disease (day
12), progression was reduced and delayed type hypersensitivity
to TBM antigen impaired. This observation suggests a possible
benefit from such therapy in humans with anti-TBM disease.
Cyclosporine administration also inhibited induction of the BN
TIN lesion. It inhibited delayed type hypersensitivity and, in
two studies, also impaired anti-TBM antibody production [75—
771. The stable analogue of PGE1 (l5S-l5-methyl PGE1) was
shown to inhibit BN TIN, and somewhat diminished circulating
and elutable anti-TBM antibody levels [78, 79]. It also inhibited
acute inflamation produced by intradermal injection of particu-
late TBM in TBM-sensitized BN rats.
Nature of the reactive TBM antigen in rats and other species
The TBM is the support for the epithelial cells of the tubule.
Antigenic differences in its various segments suggest that some-
what different composition may be related to its segmental
functional requirements. The major components of basement
membranes include Type IV collagen and several noncollage-
nous components including laminin, entactin, and heparan
sulfate proteoglycan [80]. Analysis of TBM preparations of
various purity indicated its collagenous nature (mainly Type IV)
[81—84]. Isolated rat TBM had somewhat more 3-hydroxy-
proline, glycine and hydroxylysine than GBM [85]. Of interest,
the renal cystic disease induced by feeding rats 2-amino-4,5-
diphenylthiazole was accompanied by a reversible alteration in
the polypeptide composition of the TBM [86, 87].
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The TBM antigen of the proximal tubule associated with
anti-TBM antibody disease is not shared with GBM, Bowman's
capsule or the medullary TBM. This contrasts with other
antigens in the TBM shared by GBM and other basement
membranes which can be targets of experimentally-induced
anti-GBM/TBM antibody reactions [88—90]. A 30 kD material
isolated from trypsin digests of murine or human TBM was
reported to induce anti-TBM antibody and TIN without detect-
able GBM reactions in goats and BALB/c mice [91, 92]. Using
specific absorption techniques, the BN CS TBM antigen, a
predominantly 42-45 kD moiety on SDS-PAGE, was shown to
account for about 70% of the reactivity of the eluted anti-TBM
antibody detected using the total particulate BN TBM [631. In
the same study, small amounts of reactive antigen were uncov-
ered in CS digests of the TBM Ag LEW TBM, indicating that
the reactive epitopes are present but normally sequestered in
this strain. In another approach, a monoclonal antibody reac-
tive with BN, but not LEW, TBM was used to isolate a
nephritogenic antigen of about 48 kD from CS rabbit TBM
fractions [93]. By using electron microscopy, the authors local-
ized this antigen on the most lateral aspects of the TBM
bordering the interstitium, leaving its relationship to TBM and
interstitial proteins to be determined. The peptide nature of this
material is being sought by molecular cloning [Neilson EG,
personal communications].
The chemical composition of human TBM and its age-related
changes also have been reported [81, 94]. The nature of the
reactive basement membrane antigens in human tissues is being
sought actively. Consideration is also being given to epitopes
not normally accessible for reaction by using tissue sections or
antigen preparations that are treated by chemical or enzymatic
means to expose sequestered antigen [63, 95]. Originally, hu-
man CS TBM was reported to contain a 70 kD protein reactive
with human TBM antibodies including those associated with
anti-GBM reactivity [96]. Extending the rat TBM Ag study [93]
described above, the same monoclonal antibody was used with
CS human renal basement membrane to recover a 48 kD
material that reacted with two human anti-TBM antibodies, but
not anti-GBM antibody containing sera [97]. In another study,
protein bands of 54 and 48 kD were reported reactive with
anti-TBM antibodies [981. After reduction, only the 48 kD band
remained. In that study, anti-GBM antibodies reacted with
45-50 and 25-27 kD TBM bands a reaction similar to that of
antigens recovered from CS GBM some years ago [991. Using a
different solubilization technique of 6 M guanidine-HC1/0.05 M
Tris with proteinase inhibitors, a 58 kD material apparently
unique to TBM was found reactive with human anti-TBM
antibodies [100]. These same sera were not reactive with
extracts of GBM. In this study, the 6 M guanidine solubilization
was more effective in releasing reactive antigen than was
collagenase. The variation in molecular weight as well as the
molecular origin of the reactive materials recovered by the
different means of solubilization and purification, which could
generate fragments of differing size containing similar epitopes,
remains to be defined. It will be of interest to determine the
structural relationship between the reactive TBM and GBM
antigens. The latter are now considered to be present in
noncollagenous portions of the globular NC1 domains of type
IV collagen [101].
Mouse models
The lesion induced in mice by immunization with heterolo-
gous TBM differs considerably from that in guinea pigs and rats,
particularly in its delayed onset, and much more evidence
suggests that cellular immunity is the predominant mechanism.
When anti-TBM antibody and TIN have been induced, it has
been found that the severity of the histologic changes is related
to the H-2 phenotypic trait but not the magnitude of the
antibody response [102—105]. The SJL mouse has been found to
be most susceptible. The histologic lesions developed only
slowly 6 to 7 weeks after immunization with rabbit TBM,
whereas anti-TBM antibody appeared much earlier. Recent
analysis of the anti-TBM antibodies produced among suscepti-
ble and nonsusceptible strains showed no difference in quantity
of antibody, epitopic specificity of the response, or difference in
the idiotope of the eluted anti-TBM antibody [1061.
A Thy-l.2, Lyt-2,3 T effector cell was shown to play a
prominent role in the pathogenesis of the TIN in SJL mice
[107]. Transfer of immune cells caused a lesion to develop after
several weeks but immune serum produced a less striking and
more delayed lesion [1081. The serum transfer lesion contained
somewhat more natural killer cells in the interstitial infiltrate
than in the lesion created by cell transfer. However, the lesions
were complex and also included I cells, macrophages, Ig
cells. The Lyt-2 effector cell expressed idiotypes shared with
kidney-bound anti-TBM antibody and was regulated by inter-
action of immunoglobulin genes (IgH-l) and MHC genes
(H-2K) [109]. Cells recovered from kidney infiltrates could
transfer disease in 5 days if placed under the kidney capsule. A
helper T cell line, raised from these cells and which phenotyp-
ically was Lyt-l, L3T4, was also found to transfer TIN, but
required 12 weeks. Studies suggested that the T cell line
functioned by inducing the Lyt 2 effector cell [110].
The development of the Lyt-2 effector cell in strains of mice
susceptible and nonsusceptible to murine TIN has been studied
in vitro [1111. Both Lyt-2 effector and L3T4 non-nephrito-
genic effector cells developed initially; but in the nonsusceptible
strains further development of the Lyt-2 effector cell was
inhibited, suggesting that protection against autoimmunity re-
sulted from regulation of lymphocyte preference. Preliminary
studies suggested this regulation is related to contrasuppression
[112].
A suppressor cell network capable of inhibiting the murine
TIN was induced in the mice by injection of spleen cells to
which TBM antigen had been coupled [113]. At least two
subsets of suppressor cells could be demonstrated; these have
been designated Ts-1 and Ts-2. The first was an afferent Ts-l
cell capable of binding antigen. Its phenotype was L3T4, I-J,
and TBM Ag-idiotypet In the presence of antigen, these cells
induced Ts-2 cells that were anti-idiotypic suppressors. The
Ts-2 cells were Lyt-2, I-J and were functionally restricted by
I-J and IgH-V gene products. The protection by Ts-2 cells was
induced autologously in animals that already had murine TIN
by injecting antigen coupled spleen cells, suggesting the tech-
nique as an antigen specific therapeutic strategy [114]. Soluble
suppressor factors [TsF1) from the spleen cells of mice treated
to induce suppressor cells were able to inhibit development of
interstitial lesions and were both antigen specific and geneti-
cally restricted by I-J [115]. Cloned Ts-1 cells secreted suppres-
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sor factors (TsF1) [116] and monoclonal antibody raised to the
factor precipitated a 70 kD protein and blocked suppression
mediated by the cell line. Recently it has been suggested that
sodium aurothiomalate (gold) inhibits suppressor activity; this
was inferred from a study in which gold was used to induce
murine interstitial nephritis in the usually resistant C57B1/6
mouse strain [117].
The immunosuppressive effects of PGE1 [(l5S)-15-methyl
PGE1] have been explored in the murine interstitial model [118].
Suppression of lesion development was seen with administra-
tion from time of immunization. The mechanism appears to be
via reversible inhibition of effector Lyt2 T cells by induced
soluble spleen cell products; inhibition by POEJ can be over-
come by addition of exogenous recombinant IL- 1.
There is considerable interest in whether MHC antigen
expression and modulation on renal tubular cells has an impor-
tant influence on T cell responses in allograft rejection and
autoimmune reactions [119—124]. Gamma interferon up-regu-
lates MHC Class II antigens and corticosteroids down-regulates
them [125, 126]. An MHC association with disease may signal a
T cell mechanism [127] since MHC molecules are needed for
the interaction of monocytes and T cells during antigen presen-
tation; possibly events capable of altering expression of MHC
molecules [reviewed in 128] may encourage a nephritogenic
autoimmune response, as in drug associated TIN.
Interesting preliminary studies have suggested that a murine
proximal tubular cell line, which produces 3M-l (a target
antigen of murine anti-TBM antibodies) and which has class II
MHC determinants, and secretes IL-l, could be recognized by
a cloned L3T4 helper T cell line specific for M3-1 [129]. The
cultured tubular cell supported the growth of the T cell line in a
dose-dependent fashion, which suggests that the cell might
function as an "antigen presenting cell" of its own endogenous
antigen. Such an antigen presenting mechanism could directly
relate to antigen expression and recognition on the murine
interstitial nephritis model. A second renal cell thought capable
of "antigen presentation" has been described among the Ia-
positive 1 to 2% of cells in the glomerular mesangium [1301.
Another preliminary report, addressing the reasons for suscep-
tibility and nonsusceptibility for murine TIN, suggested that
anti-TBM antibody was able to down-regulate class II MHC
expression and so decrease visibility of target epithelium in
nonsusceptible strains [131].
The experimental models of anti-TBM antibody-associated
TIN appear to be fostered by varying degrees of humoral and
cellular immune mechanisms in which the very early lesions in
the guinea pig and rat have a prominent humoral, complement,
and PMN (in the rat) component. In contrast, the somewhat
more slowly developing mononuclear phase of the disease in
guinea pigs and rats, and particularly the slowly developing
murine model, have prominent features of cellular immunity.
This makes the models in all three species valuable for studies
to quantify and separate the respective contributions of hu-
moral and cellular immunity; as well as to develop and evaluate
therapies for these two interactive mechanisms.
Anti-TBM antibody disease in humans
The pathogenic role of anti-TBM antibody-associated im-
mune mechanisms in human renal disease remains incompletely
understood. Compelling evidence such as induction of injury by
transfer of human anti-TBM antibody to nonhuman primates
has not been presented. Based on the experimental evidence in
the rat, which shows that transfer relates to quantity of anti-
body bound [681, the same effect would be predicted in humans.
Cellular immunity may also contribute as in the models of
anti-TBM antibody disease, in which its role varies with the
species.
Anti-TBM antibodies have been found in approximately 70%
of patients with anti-GBM antibody disease [96, 132, 133].
Some of these antibodies react with the TBM of only a portion
of the tubules in a cortical cross section compared to others
which are more diffusely reactive. This varied reactivity sug-
gested that more than one antigen may be involved. In patients
with anti-GBM antibody disease, the added anti-TBM reactivity
has been associated with increased tubulointerstitial inflamma-
tion [134]. The GBMITBM reactive sera can detect TBM
antigens in the TBM Ag LEW rat kidney in contrast to the
selective anti-TBM antibodies, which are nonreactive with
LEW kidney, requiring instead a TBM Agtm BN rat or human
kidney target (Table 2).
Anti-TBM antibodies with reactions confined to the TBM
have been found only in occasional patients, and then often
associated with some form of glomerular disease sometimes
complicated by Fanconi syndrome. These include the develop-
ment of anti-TBM antibodies late in the course of poststrepto-
coccal glomerulonephritis [135] and in children with presumed
immune complex forms of glomerular injury [136—138] as well
as systemic lupus erythematosus 1139].
A patient with possible milk allergy and intractable diarrhea
has been found with anti-TBM antibodies associated with a
severe membranous form of glomerular disease in which renal
eluates reacted with jejunal basement membranes as well as
TBM [Wilson CB, unpublished observations]. Anti-TBM anti-
bodies have also been noted in a patient with celiac disease and
nephrotic syndrome and two patients with "pseudolinear"
TBM staining and villous atrophy of the small intestine [137,
140]. Anti-TBM antibodies were reported in a patient with
oxalosis and chronic TIN associated with an intestinal bypass
[141].
Anti-TBM antibodies have been seen as a complication of
drug related TIN including that associated with methacillin
[142, 143], phenytoin [144], and possibly allopurinol [145]. In a
case of methicillin-associated TIN with circulating anti-TBM
antibody and TBM-bound IgG, the dimethoxyphenylpenicilloyl
(DPO) breakdown products of methicillin were bound to the
TBM, suggesting that a hapten-carrier mechanism may have
been responsible for anti-TBM antibody induction in this pa-
tient [143]. A similar mechanism has been suggested in the case
of phenytoin-associated TIN, in which anti-TBM antibodies
were present and phenytoin was found along the TBM [1441.
Anti-TBM antibodies are only found infrequently in methicillin-
associated TIN and, although probably contributing when
present, are only a partial answer to the pathogenesis of this and
other drug-associated forms of tubulointerstitial injury [146,
147].
A very limited number of patients have been noted who may
fit the definition of "primary" anti-TBM antibody disease in
which linear TBM deposits of immunoglobulin, circulating
anti-TBM antibodies and no immunologic glomerular disease
are noted [11, 1481. Spontaneous remission after anuria was
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Table 2. Similarity of nephritogenic basement membrane antigen systems in rats and humans
Ab reactivity Rats Humans
Selective TBM TBM in adjuvants induces anti-TBM Ab with TIN in
TBM Ag strains
TIN, TIN + GN, Tx
Antigen 42-45 kD [631, 48 kD [93] 70 kD [69], 48 kD [97], 58 kD 1100]
LEW TBM Ag, CS reveals TBM Ag in LEW TBM
TBM Ag to TBM Ag Tx induces anti-TBM Ab
Rare TBM Ag
TBM Ag differences can induce anti-TBM Ab
after Tx
GBM often with focal or
diffuse TBM reactivity
GBM in adjuvant induces anti-GBM Ab in TBM Ag*
strains
Goodpasture's syndrome RPGN TIN, Tx
HgCI2 induces anti-GBM Ab in BN. BN Ab reacts
with human CS GBM in RIA
Induction unknown
Antigen 25-27, 45-50 kD 1981
No GBM Ag strains found to date
27, 54 kD (99], NCI Type IV collagen [1011
Hereditary nephritis may be GBM Ag. Tx of
GBM Ag kidney to GBM Ag recipient
may induce anti-GBM Ab
Other abbreviations are: Ab, antibody; GN, glomerulonephritis; Tx, transplantation; RIA, radioimmunoassay; RPGN, rapidly progressive GN.
recorded in one such patient, an elderly woman receiving drug
therapy for arthritis [11]. TBM staining for IgG has been
subsequently reported in two maternal cousins of the initial
patient [148, 1491, raising the question of a familial disorder.
The most frequent occurrence of anti-TBM antibodies in
humans has been in renal transplant recipients [1501. Rarely,
these antibodies are induced by differences in TBM antigenicity
between the recipient and the transplant [48], as was discussed
in relation to cross strain transplantation in rats. That is, the
anti-TBM antibody recovered from the circulation or eluted
from the kidney reacts with the transplant, but not with the
patient's own kidney. More commonly, antigenic differences
cannot be detected and the reason for induction of the response
in the immunosuppressed post-transplant situation is unclear.
Anti-TBM antibodies associated with the patient's primary
disease can recur after renal transplantation [151]. Recently,
lymphocytes recovered from the allograft of a patient with
"primary" anti-TBM antibody nephritis [1481 were shown to
produce anti-TBM and anti-peritubular capillary antibodies in
vitro [1521. Circulating anti-TBM antibodies were not present
although TBM deposits were present in the transplant, leading
the authors to suggest a local production and fixation of
antibodies. Overall, the detection of anti-TBM antibodies in
transplant recipients was well below 10% and, when present,
have been noted to be transient (mean disappearance 8.6
months) [153]. Little or no pathogenicity has been associated
with the antibodies in terms of graft survival although the
contribution of the antibodies, while present, to tubulointersti-
tial injury and infiltration in the transplant remains difficult to
determine or quantify.
Other antibody reactions leading to TIN
Immune complex formation with soluble or trapped antigen
The chronic serum sickness models of renal injury produced
by daily injection of soluble serum protein antigens are compli-
cated by extraglomerular immune complex deposition including
deposits in the TBM and peritubular capillary areas [154]. In
our experience extraglomerular deposition is most striking
when very large quantities of immune complex material are
formed, as determined by the amounts of antibody produced
and the daily antigen dose given. Immune complex disease is a
dynamic condition in which antigen and antibody are free to
interchange and constantly reshape the deposit [3]. In trying to
determine why deposits accumulate, events that influence the
dynamics of this interchange need to be considered. Physical
factors may contribute; these include charge interaction [155] or
interstitial Fe receptor interaction [156] that alter movement of
antigen or antibody from a site. Secondary events such as
anti-idiotypic antibodies can change the dynamics of the inter-
action by cross linking the antibody portion of the complex
[157] and thereby may favor retention.
Ig and C3 deposits have been found in the TBM and small
vessels of the immune complex disease of the (NZB x NZW) F1
and other lupus prone mouse strains [158]. These presumed
immune complexes may be present without producing infil-
trates, which may relate to quantitative and temporal features
of the deposition as in the glomerulus.
In humans, systemic lupus erythematosus (SLE) is a disease
with relatively large quantities of circulating immune com-
plexes. Over 50% of biopsies from patients with SLE have
tubulointerstitial Ig, C3, and DNA deposits in TBM, peritubular
capillaries, and larger vessels [133, 159]. These deposits can be
helpful in making a diagnosis of SLE. The exact role of the
deposits in producing inflammation remains unclear [160—162],
but the membrane attack complex of complement (MAC)
suggests they may contribute to tubulointerstitial injury [163].
In SLE, the majority of cells infiltrating the lesions are DR T
helper cells [164]. Occasionally tubulointerstitial disease, some-
times with renal tubular acidosis, overshadowed the glomerular
disease in SLE [165]. Tubulointerstitial deposits have occasion-
ally been found in other forms of presumed immune complex
forms of glomerulonephritis and in renal allografts [133, 166—
1681.
The concept of dynamic immune complex formation moves
easily into the idea of planted antigen mechanisms. Soluble
antigenic material (endogenous or exogenous) becomes trapped
in the kidney (usually the glomerulus), usually for physico-
chemical or immunological reasons, where it is accessible to
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circulating antibody. This mechanism is well recognized in
immune glomerular injury involving cationic antigens or anti-
genie immunoglobulin molecules during autologous phases of
heterologous antibody administration [reviewed in 155, 1691.
Such a mechanism would be attractive in drug-induced immune
tubular injury; however, other than a few drug-associated
products (see above), examples are scarce [147].
Antibodies reactive with renal tubular cell antigens
The local formation of immune deposits would occur if an
antigen were present on a cell surface or released from it,
allowing an antigen-antibody reaction to occur in the immediate
extracellular environment. Such a mechanism may be respon-
sible for the striking immune complex deposition found in the
extracellular space between the TBM and the plasma mem-
brane of the tubular cell in rabbits immunized with homologous
tubular antigen fractions, human tubular brush border antigens
(Fx1A), or given repeated renal transplants [170—172]. Antibody
eluted from these deposits reacts with renal tubular brush
border and cytoplasmic antigens [173].
The tubular lesions associated with active or passive forms of
Heymann's nephritis are good examples of "selective" anti-
body-induced tubular cell injury. Rats with long-standing active
Heymann's nephritis have evidence of antibody binding to the
brush border with C3 fixation and tubular abnormalities [174,
175]. When studied in detail, brush border fixation and cytolytic
injury to proximal tubular cells correlated with high levels of
circulating antibody and the onset of proteinuria S to 7 weeks
after immunization [176]. The tubular injury was associated
with immune deposit formation at the basal areas of the cell in
the area of the TBM. When rats, rendered proteinuric with
serum sickness, are given anti-FxlA antibody, the antibody is
able to move through the glomerular filter into the tubular fluid
and react with brush border antigens (with less extensive
evidence of C3 binding), to produce widespread tubular epithe-
hal cell lysis [177]. The lesions are complement independent, as
shown in studies using recipients treated with CVF and thought
to be due to antibody-related clumping and shedding of mem-
brane fragments [178]. This mechanism of deposit formation
would be similar to glomerular lesions of Heymann's nephritis,
a lesion which is now felt to be mediated by the MAC [179—186].
Anti-tubular brush border antibodies have been reported in a
few human patients with TIN or after renal transplantation
[187—189], where they might have similar consequences.
A number of monoclonal antibodies have been raised to rat
brush border antigens and some induce glomerular deposits like
those of passive Heymann's nephritis [190—192]. One such
monoclonal that bound a 280 kD brush border antigen also
reacted with epithelial cells in the yolk sac and resulted in fetal
abnormalities when administered to pregnant rats [193]. Mono-
clonal antibodies are being developed that should help charac-
terize segments of the renal tubule and perhaps cause more
selective forms of injury. Examples of such monoclonals that
have been reported are those that identify gpl6O in proximal
tubular epithelial cells, gpl2O on cells of the proximal tubule
and portions of Henle's loop, and gp4O on cells of the distal
tubule and collecting duct [194]. Monoclonal antibodies have
already been used to isolate selected renal tubular cells and to
establish uniform renal tubular cell cultures [195, 196].
Another renal tubular antigen involved in local autologous
immune complex formation is the Tamm-Horsfall protein of the
surface of the ascending limb of the loop of Henle and distal
convoluted tubular cells [197, 198]. The intrarenal distribution
of Tamm-Horsfall protein is altered by obstructive uropathy
[199, 200]. It can be complexed by antibody at the bases of cells
synthesizing it when rats are immunized with Tamm-Horsfall
proteins [201, 202]. These immune complex deposits disappear
within 2 weeks of transplantation into an unimmunised synge-
neic rat to prevent continued exposure to circulating antibody
[203]. Mice immunized with Tamm-Horsfall protein also de-
velop immune deposits within the basal and lateral intercellular
spaces of the ascending limb in a more extensive distribution
than in the rat [204]. Similar deposits and a mild mononuclear
cell infiltrate can be produced by heterologous anti-Tamm-
Horsfall antibodies as well [205]. Rabbits develop TIN after
immunization with Tamm-Horsfall protein or homologous
urine; interstitial antibody deposits are not found in spite of the
presence of circulating anti-Tamm-Horsfall antibody [206, 207].
Peripheral lymphocytes are sensitized to Tamm-Horsfall pro-
teins and a cellular immune pathogenesis was suggested [207].
Anti-Tamm-Horsfall antibody binds to the luminal surface of
the ascending limb of the 1oop of Henle in rats rendered
proteinuric, thereby permitting antibody direct access to the
tubular fluid [208]. This type of reaction allows the study of
antibody-induced injury to the luminal aspect of cells in the
distal nephron, and is presumably analogous to anti-brush
border antibody-associated proximal tubular injury in active or
passive Heymann's nephritis.
As noted above, Tamm-Horsfall protein may move into
interstitial tissue during urinary obstruction or reflux and de-
posits, together with circulating antibody to Tamm-Horsfall
protein have been reported in a pig model of reflux nephropathy
[209, 210]. Antibodies to Tamm-Horsfall protein have been
reported in humans with urinary tract infection, often in those
with ureterovesical reflux [211]. However, it has not been
demonstrated convincingly that these antibodies are associated
with Tamm-Horsfafl deposits or that the deposits are related to
inflammation [212, 213].
Antibodies to kidney tubular cells have been reported in
association with experimental retrograde pyelonephritis in rats
or intrarenal injection of bacterial endotoxin [214, 215]. A cross
reaction between Tamm-Horsfall protein and Escherichia coli
was suggested [216]. An 1gM antibody eluted from the kidney of
a patient with glomerulonephritis associated with obstructive
uropathy reacted with renal tubular epithelium [217]. Antibod-
ies reactive with renal collecting duct cells have been noted
associated with antibodies to thyroid, gastric parietal cell, and
intrinsic factor antibodies in patients with renal tubular acidosis
[218]. Antibodies reactive with renal tubular plasma membrane
antigens and blocking PTH-induced phosphaturia have been
reported in a patient with Sjogren's syndrome and pseudohy-
poparathyroidism [219].
One might speculate that viral infections of the renal tubule
might provide a source of surface antigen for subsequent
interaction with humoral (or cellular) immune responses leading
to cytotoxic damage, using the same mechanism just described
for the models involving autologous renal tubular antigens.
Cytomegalovirus infection, for example, was associated with
TIN and infiltration of CD8 T cells [220, 221]. Such immune
reactions would be very similar to that described in this section
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except that exogenous antigens would be substituted for autol-
ogous ones.
Models of TIN in which cellular immunity plays a predominant
role
Interstitial delayed-type hypersensitivity (DTH) reactions
DTH reactions have been induced in the renal interstitium by
injection of aggregated, but not soluble, Boy gamma globulin in
rats presensitized to this antigen in adjuvant [222]. The aggre-
gated antigen presumably favored the reaction by slowing its
exit from the cortical interstitium. The lesions can be trans-
ferred with cells, but not serum. Similar studies using purified
protein derivative and dodecanoic acid conjugated BSA have
been reported [223]. Drugs or their breakdown products could
possibly be involved in a DTH-like reaction in drug-related
human TIN.
TIN induced with homologous kidney antigens
A mild mononuclear TIN has been reported in LEW rats
immunized with LEW kidney homogenate [224], and it was
possible to transfer the lesions using immune cells, but not
serum. The lesions were not associated with deposition of
immunoglobulin. Use of the LEW rat to study of cellular forms
of TIN has the advantage of minimizing anti-TBM antibody
effects due to the TBM antigen differences in this strain noted
above. DA rats sensitized to LEW cells by skin grafts develop
interstitial lesions when LEW lymphocytes were placed in the
renal cortex [225]. An extension of this mechanism via exoge-
nous antigens might be the tubulointerstitial injury associated
with lymphocytic choriomeningitis virus, which has been sug-
gested to be of cellular origin [226].
A new model of severe modular TIN lesion in the LEW rat
has been developed [227] and shown to be caused by cellular
immunity because it is easily transferred by cells recovered
from the lymph nodes of immunized donors. In these experi-
ments TBM Ag LEW rats were immunized with TBM Ag
BN RBM prepared from the extensively washed residue of
homogenized and repeatedly sonicated whole BN kidneys. By
day 9, focal macroscopic granuloma-like lesions were found
which were composed of epithelioid cells, giant cells, and
mononuclear cell infiltrates throughout the cortex and outer
medulla, often in a periglomerular location. Virtually all of the
cells within inflammatory foci stained positively for rat Ia. The
large epithelioid cells in the center of the inflammatory foci
were not stained by the pan T cell reagent 0X19 or T cell subset
reagents W3125 or 0X8; however, 50 to 60% of the surrounding
mononuclear cells were positive for 0X19 and W3125, whereas
only 1 to 5% were OX8t Ig cells made up less than 5% of the
total cell population. The lesion resulted in an elevated serum
creatinine concentration but no proteinuria or glycosuria.
The immunized LEW rats developed circulating alloantibody
reactive with BN, but not LEW, TBM by indirect immunoflu-
orescence. The antibody reacted with collagenase solubilized
BN TBM by radioimmunoassay and transferred TIN to the BN
[68]. Rarely, segments of TBM in the nodular LEW lesion
bound antibody presumably because the inflammation had
exposed normally sequestered reactive epitopes [63]. Elution
studies did not reveal specific IgG fixation in the kidneys at day
14. Later, occasional rats developed antibodies reactive with
LEW GBM!TBM (also alveolar basement membrane) antigens
similar to those reported by Sado [90, 228].
The lesion could be transferred to naive LEW rats with cells,
but not by antibody. Extensive lesions were seen by day 7 in
rats receiving immunized lymph node cells and were similar to
those of days 14 to 21 after active immunization. There were no
antibody deposits and irradiated cells did not transfer to the
lesion, thus largely excluding transfer-induced active immuni-
zation.
RBM from a number of TBM antigen rat strains are capable
of inducing the nodular LEW TIN, whereas LEW and Wistar
Furth rats, which are TBM antigen, do not contain antigens
within their RBM capable of inducing more than minimal
evidence of the LEW TIN lesion. Heterologous RBM obtained
from bovine, rabbit, or human sources produce less severe, but
morphologically similar, lesions to those of the LEW TIN
induced by BN RBM. The use of bovine RBM or TBM to
induce the lesion in LEW rats is of interest in view of the
absence of such lesions in LEW rats used as controls for TBM
injections in previous studies [43, 45]. The mild and focal nature
of the heterologous TBM-induced LEW TIN lesion may have
led to its not being noticed previously, Different immunization
schedules and adjuvant mixtures may also have contributed to
hightened cellular immune responses.
Spontaneous TIN in kdkd mice
TIN develops as an autosomal recessive in the kdkd mouse,
a congenic subtine derived from the CBA/Ca strain [229]. The
mice develop proteinuria by the age of 10 weeks, and polyuria
soon thereafter. Death occurs within a few months. The devel-
opment and progression of the disease is decreased or elimi-
nated by restricting daily food intake [230]. The TIN in these
mice appears to be cell mediated [231]. The TIN begins in the
cortex with mononuclear infiltration and tubular dilatation that
can be extensive, and is followed by scarring and contraction;
immunoglobulin deposits have not been detected and anti-
kidney reactivity has not been found in sera or renal eluates.
The disease can be transferred with kdkd cells to make CBA/Ca
bone marrow chimeras, and conversely can be prevented by
transfer of CBA/Ca cells to make kdkd chimeras. A delayed
type hypersensitivity reaction to TBM has been detected in
cyclophosphamide-treated recipients using collagenase solubi-
lized CBA/Ca TBM [232]. The cyclophosphamide was needed
to impair T cells from CBA!Ca mice capable of suppressing
development of disease [233]. Disease transfer is possible using
kdkd lymph node cells into CBA/Ca mice that had been
thymectomized, irradiated and reconstituted with T cell de-
pleted CBA/Ca bone marrow as a treatment to eliminate sup-
pressor cells. kdkd Lymph node cells placed directly under the
renal capsule of cyclophosphamide-treated CBAICa mice will
also establish the lesion. The effector cells are H-2K restricted
and of a Lyt-2, L3T4 phenotype. The onset of disease in the
kdkd mice is related to a functional inactivation of suppressor T
cells normally present in young kdkd and CBAICa mice; this is
mediated by an antigen-specific set of countersuppressor T cells
[233]. A parallel has been suggested between the kdkd mouse
disease and the possible autoimmune pathogenesis of medullary
cystic disease-familial juvenile nephronophthisis complex [234].
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Cellular immune mechanisms in human TIN
The LEW rat TIN described above has striking histologic
similarity to the granulomatous nephritis found in humans
complicating drug reactions and other conditions including
sarcoidosis, tuberculosis, and Wegener' s granulomatosis [235,
236]. The major contribution of cellular immunity in the LEW
model suggests that immune cells play a role in the granuloma-
tous human counterpart.
Other forms of human TIN with prominent mononuclear
interstitial infiltrates without detectable immune deposits
should also be suspected of having a cellular immune pathogen-
esis. For example, there are descriptions of patients, often
adolescent girls, who have acute TIN and uveitis associated
with variable hypergammaglobulinemia and circulating immune
complexes. Some patients also have an eosinophilic interstitial
infiltrate and granulomas in bone marrow, with generally neg-
ative renal immunofluorescence findings [237—241].
The extent that cellular immunity contributes to human TIN
remains to be defined. Several studies have reported the pres-
ence of large numbers of interstitial T cells of somewhat varying
CD41/CD8 patterns, often with Ia positive (activated) or
cytotoxic T cells in patients with TIN as well as various other
glomerulonephritides including minimal change nephropathy
and SLE [242—250], cytomegalovirus-associated TIN [221], and
renal allografts [251]. The infiltrates in TIN associated with
Sjogren's syndrome are mainly CD4 (helper/inducer) and
nodules of B cells may also be present [252, 253]. TIN related to
drug reactions also contains prominent T cell infiltrates but
insufficient cases have been studied to determine whether
CD8 T cells are more prominent in patients with antibiotic and
nonsteroidal anti-inflammatory drug-related TIN, compared to
other drug-related causes of TIN in which CD4 cells predom-
inate [254—257].
Other considerations for inciting tubulointerstitial inflammation
The possibility of mediator activation in tubulointerstitial
renal tissue independent of specific immune responses is an
additional consideration. Using sections of normal rat or human
kidney, the brush border area of the proximal tubule and walls
of renal vessels have been shown to activate the alternative
complement pathway in vitro [258, 259]. Brush border localiza-
tion of C3 with Clq or C4 has also been suggested to correlate
with urinary C3 excretion in humans [260].
Complement components including the MAC have been
found frequently in the TBM area of kidneys with chronic
interstitial injury [261]. The idea has been advanced that in-
creasing ammonia seen with reduction in renal mass or hypo-
kalemic nephropathy may activate the alternative complement
pathway non-enzymatically leading to C3 deposition [262, 263].
Dietary NaHCO3 supplementation of rats with these renal
problems reduces C3 deposition and may reduce tubulointersti-
tial injury. Whether other immune and inflammatory mediator
systems may be activated in the extreme variation from normal
homeostatic composition (waste products, electrolytes, molar-
ity, etc.) seen in different areas of the kidney remains to be
defined.
Conclusions
Model systems provide a large number of clues that can be
applied to unravel and quantitate the contributions of humoral
and cellular immune mechanisms and their mediator pathways
that lead to injury in the tubulointerstitial areas of the human
kidney. Indeed examples of most model systems have been
described with varying certainty. Direct translation of the
model based information to the human situation is often limited
and difficult. Renal biopsy samples are small, infrequent, and
the timing of collection is often not appropriate or repeatable.
Development of new models, particularly for drug-related
forms of TIN, will permit sequential sampling to provide
needed additional mechanistic insights to allow better under-
standing and therapeutic manipulation of the human counter-
parts.
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